There is a large body of literature investigating the mechanism(s) potentially responsible for the beneficial effects of SGLT2 inhibitors in patients with heart failure with or without diabetes as summarized in several review articles [115–120] that could relate a reduction in AF via improvements in ventricular function. This evidence concerns the gene SLC5A2 and heart failure.